Cipla, a leading Indian pharmaceutical company, reported a significant decline in its fourth-quarter financial performance. The company's consolidated net profit fell 54.6% year-on-year to ₹555 crore ($58 million) for the quarter ending March 31, falling short of analysts' expectations of ₹705 crore. Total revenue from operations also decreased by 2.8% to ₹6,541 crore, which was below the anticipated ₹6,749 crore. The drop in revenue was primarily attributed to a 26% decline in sales in the crucial North American market, which accounts for a significant portion of Cipla's total sales. In contrast, the Indian market, Cipla's largest by sales, saw a 15% increase in revenue, reaching ₹3,007 crore. The company's total expenses rose by 8.5% to ₹1,882 crore, driven by increased costs and an impairment charge of ₹42.02 crore on associates. Despite these challenges, analysts predict continued pressure on U.S. sales due to erosion in key products, although Cipla's shares rose 4.23% in afternoon trading, despite a 14.3% decline in stock value this year. The company also announced a dividend of ₹13 per share.